-
Mashup Score: 80Home - 29 day(s) ago
With ge nomic and protein biomarker analysis now a cornerstone of personalized cancer care, translational advancements and novel methodologies play a powerful role in improving patient outcomes. The Third Transatlantic Exchange in Oncology, led by thought leaders from Dana-Farber Cancer Institute and Gustave Roussy with the support of L’ Institut Servier, examines the utility of liquid biopsy as a window into oncogenic activity across the disease pathway for a multitude of cancers. Join us in Boston or
Source: na.eventscloud.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 80Home - 1 month(s) ago
With ge nomic and protein biomarker analysis now a cornerstone of personalized cancer care, translational advancements and novel methodologies play a powerful role in improving patient outcomes. The Third Transatlantic Exchange in Oncology, led by thought leaders from Dana-Farber Cancer Institute and Gustave Roussy with the support of L’ Institut Servier, examines the utility of liquid biopsy as a window into oncogenic activity across the disease pathway for a multitude of cancers. Join us in Boston or
Source: na.eventscloud.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 77Home - 3 month(s) ago
With ge nomic and protein biomarker analysis now a cornerstone of personalized cancer care, translational advancements and novel methodologies play a powerful role in improving patient outcomes. The Third Transatlantic Exchange in Oncology, led by thought leaders from Dana-Farber Cancer Institute and Gustave Roussy with the support of L’ Institut Servier, examines the utility of liquid biopsy as a window into oncogenic activity across the disease pathway for a multitude of cancers. Join us in Boston or
Source: na.eventscloud.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12nd Transatlantic Exchange Program focusses on Artificial Intelligence and Data Science in Oncology - Dana-Farber Cancer Institute | Boston, MA - 12 month(s) ago
The 2nd Transatlantic Exchange Program program, focussing on Artificial Intelligence (AI) and data science in oncology, is summarized.
Source: www.dana-farber.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension. This triplet therapy could become a standard of care for these patients.
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet-
3/ Another @US_FDA approved triplet therapy in de novo #mCSPC: abiraterone (+ ADT + docetaxel) improves OS and radiographic PFS compared to SOC±RT in the #PEACE-1 trial with modest⬆️toxicity (mainly HTN). #Fizazi @AlbertoBossial @GustaveRoussy @TheLancet https://t.co/1FaUwjpwLI https://t.co/ELMnwxcTKl
-
-
Mashup Score: 1
93 Background: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) show antitumor activity in mCRPC/DDRm pts treated with novel hormonal therapy (NHT). TALAPRO-1 is an open-label study evaluating TALA (a potent PARP inhibitor/trapper) in men with mCRPC/DDRm. We report a planned interim analysis (IA; Dec 2019). Updated results at a Sep 4 2020 cut-off, available in November 2020, will be…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
The 3rd transatlantic exchanges between @DanaFarber and @GustaveRoussy happening April 12 in @CityOfBoston —come join us in person or virtually ! Topic: liquid biopsies in Cancer! @LGlimcherMD @barlesi @FAndreMD #Fizazi @OncoAlert logy https://t.co/5mHqMXghMd https://t.co/jsz6kkPQnS